Highlights Shionogi & Co., Ltd.

Equities

4507

JP3347200002

Pharmaceuticals

Delayed Japan Exchange Other stock markets 22:19:24 2026-05-20 EDT			5-day change	1st Jan Change
3,030.00 ^JPY	-0.16%		-1.50%	+6.65%

05-13	Shionogi Covid Pill Reduced Infection Risk in Late-Stage Study	MT
05-13	Bain-backed Tanabe Pharma targets three new drug launches a year in Japan	RE

Highlights

05-13	Shionogi & Co., Ltd. Announces Results from Its Global, Double-Blind, Randomized, Placebo-Controlled Phase 3 Study	CI
05-12	Shionogi & Co., Ltd. Proposes Year End Dividend for the Year Ended March 31, 2026, Payable on June 25, 2026 and Provides Dividend Guidance for the Second Quarter of Year Ending March 31, 2027	CI
05-12	Shionogi & Co., Ltd. Provides Year End Dividend Guidance for the Year Ending March 31, 2027	CI
05-12	Shionogi & Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2026 and for the Year Ending March 31, 2027	CI
05-12	Shionogi & Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2026	CI
04-27	Shionogi to Absorb Torii Pharmaceutical in April 2027 Merger	MT
04-08	Shionogi & Co receives contract with U.S. government through BARDA's Project BioShield to enhance national preparedness for drug-resistant bacterial threats	RE
04-07	Shionogi & Co., Ltd. Presents New Real-World Data Highlighting Clinical Effectiveness of Fetroja/Fetcroja (Cefiderocol) in Mbl-Producing Enterobacterales Infections	CI
04-02	Shionogi Completes $2.5 Billion RADICAVA Rights Acquisition	MT
04-01	Shionogi & Co: acquisition of all rights to Radicava (edaravone) is expected to be immediately accretive in fiscal year 2026, adding approximately USD $700 million in annual global sales	RE
03-29	Final dividend	FA
03-23	Shionogi & Co Ltd - to acquire 50% stake in Shionogi-Apnimed Sleep Science for $100 mln from Apnimed Inc	RE
03-23	Shionogi & Co., Ltd. entered into an equity transfer agreement to acquire 50% remaining stake in Shionogi-Apnimed Sleep Science, LLC from Apnimed, Inc. for $150 million.	CI
03-23	Shionogi & Co., Ltd. Announces Approval Of Supplemental Indication For XOCOVA Tablets	CI
03-23	Shionogi - To Raise 360 Billion Yen In Bridge Loans From Sumitomo Mitsui Banking Corp	RE
03-19	Shionogi & Co., Ltd. Announces First Patients Enrolled in Global Phase 2 Clinical Trial in Adults with Late-Onset Pompe Disease	CI
02-26	Shionogi & Co Ltd - Application for manufacturing and marketing approval of a new lotion formulation for atopic dermatitis treatment "Corectim" in Japan	RE
01-30	Shionogi & Co.'s Nine-Month Profit Jumps 18%	MT
01-29	Shionogi & Co., Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2025	CI
01-20	Shionogi & Co Invests $2.13 Billion to Replace Pfizer as ViiV Healthcare Shareholder	MT
01-20	Pfizer to exit ViiV Healthcare in $1.9 billion deal as Shionogi doubles stake	RE
01-19	Shionogi to Acquire Additional Shares in ViiV Healthcare for $2.1 Billion	DJ
01-19	Shionogi & Co Ltd to acquire 11.7% voting rights in VIIV HEALTHCARE from GSK and Pfizer	RE
01-08	Shionogi China receives approval from National Medical Products Administration for cefiderocol for treatment of complicated urinary tract infections	RE
12-22	Shionogi & Co Ltd - Planned acquisition of global rights to Tanabe Pharma's Radicava ORS and IV Radic	RE